Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital

Intercept Pharmaceuticals (ICPT) PT Raised to $217 at Wedbush

Wedbush raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $217.00 (from $203.00) while maintaining a Outperform rating.

Goldman Sachs Upgrades Intercept Pharmaceuticals (ICPT) to Buy

(Updated - August 6, 2018 7:41 AM EDT)

(updated to correct prior recommendation)

Goldman Sachs upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Buy with a price target of $157.00 (from $46.00).

Analyst Salveen Richter says the company's Ocaliva in NASH is the most improtant... More

Intercept Pharmaceuticals (ICPT) PT Raised to $69 at Cantor Fitzgerald

Cantor Fitzgerald raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $69.00 (from $58.00) while maintaining a Neutral rating following the company's 2Q earnings report. For the quarter, ICPT reported net Ocaliva revenues of $43.2 million, slightly above estimates of $42.0 million.

Despite the... More

Intercept Pharmaceuticals (ICPT) PT Raised to $120 at Cowen

Cowen raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $120.00 (from $88.00) while maintaining a Outperform rating.

Analyst Ritu Baral commented, "ICPT 2Q earnings beat revenue expectations: the Ocaliva launch is showing early signs of stabilization and renewed growth. Next... More

Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($2.58), $0.26 better than the analyst estimate of ($2.84). Revenue for the quarter came in at $43.58 million versus the consensus estimate of $41.19 million.

its financial results for the quarter ended June 30, 2018.

During the first half of 2018, we made good progress executing against our key strategic priorities in our Phase 3 NASH... More